Literature DB >> 23286224

Post-transcriptional processing of genetic information and its relation to cancer.

Lr McNally1, U Manne, W E Grizzle.   

Abstract

During the development, progression and dissemination of neoplastic lesions, cancer cells hijack normal pathways and mechanisms, especially those involved in repair and embryologic development. These pathways include those involved in intercellular communication, control of transcription, post-transcriptional regulation of protein production including translation of mRNAs, post-translational protein modifications, e.g., acetylation of proteins, and protein degradation. Small, non-translatable RNAs, especially microRNAs (miRs), are Important components of post-transcriptional control. MiRs are produced from areas of the genome that are not translated into proteins, but may be co-regulated with their associated genes. MiRs bind to the 3' untranslated regions of mRNAs and regulate the expression of genes in most cases by either promoting the degradation of mRNA and/or inhibiting the translation of mRNAs into proteins; thus, miRs usually cause a decrease in protein levels that would be expected if the mRNAs were translated normally. It is early in our understanding of how miRs affect neoplastic processes, but miRs are expressed differentially in most cancers and have been associated with tumor progression, chemoresistance and metastasis. MiRs are present in nanovesicles, such as exosomes, and thus are likely involved in intercellular communication, especially in neoplasia. MiRs are attractive targets for novel therapies of cancer as well as potential biomarkers that might be useful for early detection and diagnosis, and for prediction of therapeutic efficacy. MiRs also could aid and in determining prognosis, evaluating novel therapies, and developing preventive strategies by their use as surrogate end points.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23286224      PMCID: PMC4091847          DOI: 10.3109/10520295.2012.730152

Source DB:  PubMed          Journal:  Biotech Histochem        ISSN: 1052-0295            Impact factor:   1.718


  41 in total

1.  Translating MicroRNA discovery into clinical biomarkers in cancer.

Authors:  Scott A Waldman; Andre Terzic
Journal:  JAMA       Date:  2007-05-02       Impact factor: 56.272

Review 2.  Metastamirs: a stepping stone towards improved cancer management.

Authors:  Nicole M A White; Eman Fatoohi; Maged Metias; Klaus Jung; Carsten Stephan; George M Yousef
Journal:  Nat Rev Clin Oncol       Date:  2010-11-02       Impact factor: 66.675

Review 3.  MicroRNAs and metastasis: little RNAs go a long way.

Authors:  Derek M Dykxhoorn
Journal:  Cancer Res       Date:  2010-07-27       Impact factor: 12.701

Review 4.  MicroRNAs and prostate cancer.

Authors:  Valeria Coppola; Ruggero De Maria; Désirée Bonci
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

5.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.

Authors:  Li Ma; Julie Teruya-Feldstein; Robert A Weinberg
Journal:  Nature       Date:  2007-09-26       Impact factor: 49.962

6.  miRNAs are stable in colorectal cancer archival tissue blocks.

Authors:  Liselle Bovell; Chandrakumar Shanmugam; Venkat R Katkoori; Bin Zhang; Emily Vogtmann; William E Grizzle; Upender Manne
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

Review 7.  MetastamiRs: non-coding MicroRNAs driving cancer invasion and metastasis.

Authors:  Cesar Lopez-Camarillo; Laurence A Marchat; Elena Arechaga-Ocampo; Carlos Perez-Plasencia; Oscar Del Moral-Hernandez; Elizabeth J Castaneda-Ortiz; Sergio Rodriguez-Cuevas
Journal:  Int J Mol Sci       Date:  2012-01-27       Impact factor: 6.208

8.  miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT.

Authors:  X Xiang; X Zhuang; S Ju; S Zhang; H Jiang; J Mu; L Zhang; D Miller; W Grizzle; H-G Zhang
Journal:  Oncogene       Date:  2011-04-04       Impact factor: 9.867

Review 9.  The fascinating world of RNA interference.

Authors:  Afsar Raza Naqvi; Md Nazrul Islam; Nirupam Roy Choudhury; Qazi Mohd Rizwanul Haq
Journal:  Int J Biol Sci       Date:  2009-01-15       Impact factor: 6.580

10.  Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer.

Authors:  Parag P Shah; Lauren E Hutchinson; Sham S Kakar
Journal:  J Ovarian Res       Date:  2009-08-27       Impact factor: 4.234

View more
  6 in total

1.  Quality management of biorepositories.

Authors:  William E Grizzle; Elaine W Gunter; Katherine C Sexton; Walter C Bell
Journal:  Biopreserv Biobank       Date:  2015-06       Impact factor: 2.300

2.  Use of human specimens in research: the evolving United States regulatory, policy, and scientific landscape.

Authors:  Marianna J Bledsoe; William E Grizzle
Journal:  Diagn Histopathol (Oxf)       Date:  2013-09

Review 3.  MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans.

Authors:  J Jones; W Grizzle; H Wang; C Yates
Journal:  Biotech Histochem       Date:  2013-08-01       Impact factor: 1.718

4.  Differential expression of microRNA between triple negative breast cancer patients of African American and European American descent.

Authors:  William M MacCuaig; Alexandra Thomas; Juan C Claros-Sorto; Jorge G Gomez-Gutierrez; Adam C Alexander; Elizabeth A Wellberg; William E Grizzle; Lacey R McNally
Journal:  Biotech Histochem       Date:  2022-01-04       Impact factor: 1.834

Review 5.  Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions.

Authors:  Huang-Ge Zhang; William E Grizzle
Journal:  Am J Pathol       Date:  2013-11-21       Impact factor: 4.307

6.  mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.

Authors:  Bo Liu; Rui Wang; Hongyan Liu
Journal:  Biomed Res Int       Date:  2021-05-15       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.